A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes.
Phase of Trial: Phase I/II
Latest Information Update: 13 May 2014
At a glance
- Drugs Vorinostat (Primary) ; Cytarabine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 25 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 25 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2008 New trial record.